Robin Lachmann

11PUBLICATIONS
66CO-AUTHORS
Gene and molecular therapyMajor global burdens of diseaseCardiology (incl. cardiovascular diseases)Medical molecular engineering of nucleic acids and proteinsProsthetics and orthotics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 10, 2026
Advances in Therapeutics-Enzyme Replacement Therapy: Long-Term Evaluation and New Approaches.

Robin Lachmann

|Feb 16, 2026
Enzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis.

Mark Corbett, Chinyereugo Umemneku-Chikere, Sarah Nevitt

|Feb 06, 2026
Cardiovascular Morbidity and Mortality in Fabry Disease.

Emanuele Monda, Athanasios Bakalakos, Annamaria Del Franco

|Nov 03, 2025
Re-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.

Matthew Walton, Nyanar J Deng, Mark Corbett

|Apr 25, 2023
Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults.

Robin H Lachmann, George A Diaz, Melissa P Wasserstein

|Feb 28, 2023
Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment.

Peter Kamenicky, Karine Briot, Maria Luisa Brandi

Pageof 2

Frequent Collaborators

2 joint publications

Maria Luisa Brandi

2 joint publications

Matthew Walton

2 joint publications

Karine Briot

2 joint publications

Annabel Nixon